CMT Asset Management’s Gilead Sciences GILD Stock Holding History

CMT Asset Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,322	Closed	-$512K	–	55
2017 Q3	$512K	Buy	+6,322	New	+$483K	0.02%	145
2017 Q1	–	Sell	-39,902	Closed	-$2.81M	–	177
2016 Q4	$2.86M	Buy	39,902 +11,991	+43%	+$891K	0.13%	107
2016 Q3	$2.21M	Buy	+27,911	New	+$2.27M	0.1%	125
2016 Q2	–	Sell	-9,271	Closed	-$823K	–	201
2016 Q1	$852K	Sell	9,271 -19,785	-68%	-$1.78M	0.06%	149
2015 Q4	$2.94M	Buy	+29,056	New	+$3.02M	0.15%	120
2015 Q3	–	Sell	-39,663	Closed	-$4.41M	–	201
2015 Q2	$4.64M	Sell	39,663 -44,205	-53%	-$4.83M	0.29%	91
2015 Q1	$8.23M	Buy	83,868 +40,822	+95%	+$4.15M	0.6%	51
2014 Q4	$4.06M	Buy	43,046 +39,183	+1,014%	+$4.05M	0.24%	85
2014 Q3	$411K	Buy	+3,863	New	+$378K	0.02%	143

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CMT Asset Management's GILD Position: Q4 2017 in Review

CMT Asset Management sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 6,322 shares — an estimated $512K sold.

CMT Asset Management first reported a position in GILD in Q3 2014 and held it in 9 quarters. The position peaked at $8.23M in Q1 2015. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

CMT Asset Management reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
CMT Asset Management sold 6,322 Gilead Sciences shares in Q4 2017, an estimated $512K.
CMT Asset Management first reported a position in Gilead Sciences in Q3 2014 and held it in 9 quarters.
CMT Asset Management's Gilead Sciences position peaked at $8.23M in Q1 2015.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on CMT Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.